Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients

Key facts

Sponsor

University Hospital, Brest

Principal Investigator

Jean-Christophe Ianotto, MD

CHRU de Brest

Enrollment

286 enrolled

Eligibility

18 years · All sexes

Timeline

2014 – 2015

Study locations (1)

• CHRU de Brest, Brest, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07340138
  Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
  Novartis Pharmaceuticals
• RECRUITINGPHASE3NCT07357727
  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
  Novartis Pharmaceuticals
• RECRUITINGPHASE1NCT07469891
  A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
  Prelude Therapeutics
• RECRUITINGNCT06976918
  Registry Platform Myelofibrosis and Anemia
  iOMEDICO AG
• RECRUITINGNCT07203768
  A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
  FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
• RECRUITINGPHASE2NCT06517875
  Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
  GlaxoSmithKline
• RECRUITINGNANCT06734637
  Efficacy and Safety of Peginterferon in ET and PV.
  Zhenya Hong
• RECRUITINGPHASE1NCT06343805
  A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
  Ajax Therapeutics, Inc.

See all trials for Essential thrombocythemia →